SEARCH

SEARCH BY CITATION

Keywords:

  • Antibodies;
  • influenza;
  • pandemic;
  • public health response;
  • serological studies

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

Please cite this paper as: Laurie et al. (2013) Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting. Influenza and Other Respiratory Viruses 7(2) 211–224.

Background  Serological studies can detect infection with a novel influenza virus in the absence of symptoms or positive virology, providing useful information on infection that goes beyond the estimates from epidemiological, clinical and virological data. During the 2009 A(H1N1) pandemic, an impressive number of detailed serological studies were performed, yet the majority of serological data were available only after the first wave of infection. This limited the ability to estimate the transmissibility and severity of this novel infection, and the variability in methodology and reporting limited the ability to compare and combine the serological data.

Objectives  To identify best practices for conduct and standardisation of serological studies on outbreak and pandemic influenza to inform public policy.

Methods/Setting  An international meeting was held in February 2011 in Ottawa, Canada, to foster the consensus for greater standardisation of influenza serological studies.

Results  Best practices for serological investigations of influenza epidemiology include the following: classification of studies as pre-pandemic, outbreak, pandemic or inter-pandemic with a clearly identified objective; use of international serum standards for laboratory assays; cohort and cross-sectional study designs with common standards for data collection; use of serum banks to improve sampling capacity; and potential for linkage of serological, clinical and epidemiological data. Advance planning for outbreak studies would enable a rapid and coordinated response; inclusion of serological studies in pandemic plans should be considered.

Conclusions  Optimising the quality, comparability and combinability of influenza serological studies will provide important data upon emergence of a novel or variant influenza virus to inform public health action.


Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

The value of serological studies to inform the public health response was apparent in the 2009 influenza A(H1N1) pandemic (the 2009 pandemic) despite the major challenges in conducting them. Serological studies are able to measure the antibodies that most people develop in response to infection with an antigenically novel influenza virus. This antibody response develops within 2–3 weeks of infection1–3 and may persist at a detectable level for months, providing protection against further challenge with the same virus. Influenza serological assays, such as haemagglutination inhibition (HI) or microneutralisation (MN), quantify these virus-specific antibodies, as an indicator of infection. Serological assays can confirm past infection in the absence of positive virological testing4,5 and regardless of clinical presentation. Serology may detect both symptomatic and asymptomatic infection. This provides the most reliable measure of total infection with a novel pathogen in a population. Combining serological, epidemiological and clinical data improves clinical disease definitions, enables estimation of the severity and transmissibility of an emerging virus and can identify population groups that have been infected versus those that remain susceptible. Furthermore, with samples obtained prior to widespread transmission, previous infection or vaccination to antigenically similar viruses can be identified and the level of serological reactivity to the new virus inferred. These data can be used directly and within transmission models to predict the impact of infection and disease, and assess mitigation strategies, thereby informing public health policy and allowing for the adjustment of planning assumptions and countermeasures (Table 1).6–8

Table 1.   Potential contribution of early serological data to mitigating the impact of influenza pandemics
‘Known Unknown’ of influenza pandemicsRationale for knowing – the actions that may follow
  1. Adapted from ECDC’s concept of pandemic known unknowns (81) and (8).

Whether current seasonal vaccines are likely to be effective against the new pandemic virusWhether or not to offer existing seasonal vaccine before new pandemic influenza-specific vaccine becomes available
Susceptibility of a population to the novel infection and then incidence of infection and disease by age groupTarget interventions and refine countermeasures, for example, who to give antiviral drugs and/or pandemic influenza-specific vaccines
Key parameters for modelling and estimations: proportions of infections that are symptomatic and asymptomatic, effective reproductive number R (transmissibility)Modelling of current and future scenarios to allow rapid re-casting of planning assumptions and resource deployment (now-casting and fore-casting)
The severity of the pandemic as inferred from a number of parameters including cumulative attack rate and case or infection fatality rateThe level of public health response proportionate to the threat

A large number of serological studies were conducted for the 2009 pandemic providing a comprehensive picture for many parts of the world. The extensive use of serology to ascertain population infection rates to the 2009 pandemic virus was particularly impressive given the inclusion of serology in only a limited number of pandemic preparedness plans.9–11 Shortly after the onset of the 2009 pandemic, standard virus strains and sera were made available and serological correlates of infection were established.1,12,13 Early studies demonstrated the prevalence of pre-existing cross-reactive antibodies was age and location dependent,12–14 and rapid assessment suggested a lack of protection through seasonal A(H1N1) vaccination.12,13 However, despite the efforts to gather and analyse samples in many countries5,15–17 technical and logistical challenges (Table 2) meant there were no early publications using sera from close contacts to identify symptomatic and asymptomatic infections. As a result, essential information to aid in calculating the transmissibility and severity of this emerging infection was greatly limited. Rather, severity and transmissibility were inferred from non-laboratory confirmed symptomatic studies from early outbreaks18–21 and animal infection studies (Figure 1).14,22–23 Although the basic reproductive number can be estimated accurately without good knowledge of asymptomatic infection, variation in infection rates between age groups, for example (i.e. children and adults) cannot be estimated. The degree of variation in infection rates between infectious subgroups greatly influences the size of an epidemic. Risk factors associated with severe outcomes were primarily identified by clinical and epidemiological studies.24–27 The majority of serological studies were published after widespread virus transmission and measured the cumulative age-specific incidence rates in populations.1,28–37 Later studies also assessed attack rates in vulnerable populations and healthcare workers,30,38–40 risk factors for infection,30,37,39–41 the effectiveness of mitigation strategies,42,43 transmission dynamics within populations5,16,44 the severity of infection in different age groups37 and the extent of asymptomatic disease5,28,45 (Figure 1). These studies informed public health policy by addressing some of the ‘known unknowns’ of the novel virus. Although an international antibody standard was developed in a effort to standardise laboratory results,46 it was not widely used for standardisation of seroprevalence studies, in part due to limited knowledge of its availability. Therefore, variability in data collection, analysis and reporting (Table 2) meant it was not always possible to ascertain whether differences between study results were population and location specific or reflected assay and other methodological distinctions.47

Table 2.   Common challenges faced by researchers performing influenza serological studies in 2009 and 2010
Overall challengeKey difficulties and concerns
Timeliness in responding to initial outbreaksNecessity for rapid ethics approval and funding decisions, unless study was based on pre-existing surveillance (1)
Availability of clinical and laboratory staff
Rapid training of staff to collect and process samples
Development of consistent sampling procedures
Patient access and retention low, particularly when serial sampling required
Laboratory capacity overwhelmed and difficult to prioritise virological and serological work
Assay development, standardisation and up-scaling in testing laboratoriesHandling virus of unknown infectivity and severity
Time constraints for assay development: virus-specific HI and MN assays require up to 6 weeks development (82, 83)
Laboratory capacity and storage for expected surge activity
Variability in laboratory protocols resulting in variability in titres across laboratories (52–54)
– Laboratory variability minimised by use of an international 2009 pandemic antibody standard (09/194) (46), but awareness of standard limited
Data gathering for samples: accompanying information may inform risk factorsMajority of studies used residual sera with sample data restricted by ethical requirements
Most studies insufficiently powered to detect risk factors in real time
Sampling at the most appropriate time during the first wave and performing assays with age-stratified background controlsProspective collection of pre-pandemic samples limited by the narrow timing between identification of the novel virus and subsequent widespread infection (28, 30–33, 41)
Window of collection of samples for post-first wave infection analysis limited by the imminent availability of matched vaccine
Asynchrony of pandemic waves meant sampling at the end of the pandemic wave was difficult for some studies (1, 34)
Variability in data collection and reporting practisesVariability in pandemic waves made timing of post-first wave studies difficult to compare
Data were shared but common protocols and methodology was not established
Ethical issues when designing/conducting studiesNeed for approvals from several ethics committees for multi-site studies resulted in delays and duplication of effort
Risk that the validity of studies would be compromised when different sites placed alternate conditions on investigators
image

Figure 1.  The time course of the initial pandemic wave in the Northern and Southern Hemispheres and proportion of countries with reported cases, after the identification of the novel virus in mid-April 2009 (inline image). The working classification for serological studies according to time of sample collection and study objective is shown in this context, by shaded regions (pre-pandemic, outbreak, pandemic, inter-pandemic). Location and reference (superscript) of studies over time are shown. The earliest published serological studies in 2009 described assay sensitivity and specificity (♦), the cross-reactive pre-pandemic antibody responses (bsl00072) and demonstrated a lack of protection from seasonal vaccines (*). In 2010, serological studies describing the first wave of infection (inline image), clinical identifiers of infection (□), household transmission (inline image), risk factors for infection (•) and mitigation strategies (○) were published (shown are known serological studies until October 2010). The earliest published epidemiological outbreak studies (⋄) and animal infection and transmission studies (¥) are shown for comparison.

Download figure to PowerPoint

In the light of the challenges encountered (Table 2) and the potential value of influenza serological studies, the World Health Organisation (WHO) called for greater standardisation of such studies.47 To facilitate this goal, an international meeting led by the Public Health Agency of Canada was held in Ottawa in February 2011 with participation from public health authorities and researchers from the disciplines of epidemiology, virology, immunology, mathematical modelling and ethics (web address pending). The goal of the meeting was to foster consensus-building and standardisation on how to improve the timing, quality, and reporting of outbreak and pandemic influenza serological studies. An Expert Committee was formed following the meeting to build on the consensus forged during the meeting and develop guidance for advancing future influenza serological studies.

Guidance for best practices

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

Adopt a common framework for serological studies and standardise methodology and reporting practices

Serological studies may address a number of different objectives depending on their timing. Because of the many different types of studies that are possible, it is useful to have a common framework (Table 3). We recommend a working classification for presentation of serological studies according to the time that serum specimens were obtained: pre-pandemic studies evaluate the level of antibodies or reactivity to the pandemic strain in samples collected prior to the onset of the pandemic, outbreak studies evaluate the sera of early cases and their close contacts, pandemic studies assess the degree of infection in a larger population once widespread transmission is known to have occurred and inter-pandemic studies assess the extent of serological immunity when infection incidence has fallen to levels more typical of seasonal influenza. This is preferable to identifying studies according to local ‘epidemiological waves’, which may be difficult to define and are typically asynchronous across the world, making comparisons by waves difficult (Figure 1). Because of the plethora of information that can be obtained, the experimental and public health objective of each serological study needs to be clearly identified (Table 3).

Table 3.   Serological studies for influenza. The study classification (pre-pandemic, outbreak, pandemic, inter-pandemic) is based on the timing of serum sample collection
Classification & Overall ObjectiveKey Serological Study AimsPublished examples of 2009 pandemic serological studiesStudy Design OptionsRequirements for Study*Enabling strategies*
  1. The overall objective for each classification is defined and the aims of key serological studies are identified. The most appropriate design options, essential requirements and enabling strategies to perform informative serological studies in a timely manner are described. *All studies require adequate funding.

PRE-PANDEMIC –to develop assays and assess population susceptibilityDevelop assays – provide sensitivity and specificity controls(1–3, 13)Longitudinal study – at least two bleeds collected at acute and convalescent timepoints from individuals with virologically-confirmed infectionAccess to patientsPrior ethics approval
High patient retentionOutbreak response team to collect patient samples and clinical data
Timely swab, sera and clinical data collection
Identify the magnitude and kinetics of the serological response in confirmed cases(1–3)Higher containment laboratory facilitiesCross-training of laboratory staff
Potential for surge capacity in testing laboratory
Identify the prevalence of pre-existing cross-reactive antibodies by age group(1, 12, 14, 84–91)Age-stratified cohort or cross-sectionalAge-stratified serological samples collected before emergence of novel influenza virusNational serum bank
Sample size depends on estimated attack rate and precision requirements
OUTBREAK – to characterise a novel or variant virus and identify the potential for infectionIdentify potential protective effect of current seasonal vaccine(12, 13)Age-stratified cohort or cross-sectional – with vaccine historyAppropriate pre-vaccination serological baseline control collected before emergence of novel influenza virusSera collected for vaccine cross-reactivity studies as part of routine influenza surveillance
Establish transmission dynamics of novel strain(5, 15–17, 44)Age-stratified cohort or cross-sectionalTimely swab, sera and clinical data collection from individuals and contacts in early outbreaks, that is, schools, households, military facilitiesPrior ethics approval
Provide the denominator for severity assessment(5, 28, 37, 45)Sample size dictated by location of outbreakEstablished prospective representative cohort
Appropriate pre-outbreak, age-stratified serological baseline control. A pre-established cohort may have pre-outbreak serum samples, whilst a reactive cohort would require collection of acute blood samplesOutbreak response team to collect patient and contact samples and clinical data
Reveal the extent of asymptomatic illness National serum bank for cross-sectional studies
Inform development of clinical and subclinical case definitions(4)
Assay development
Assist in identifying risk factors for, and multipliers of, infection or severity(30, 37, 39–41)Age-stratified cohort or cross-sectionalControl group with same exposure to infectionPrior ethics approval
Detailed data collection to eliminate confoundersEstablished prospective representative cohort
Sample size depends on estimated attack rate and precision requirements
Appropriate pre-outbreak, age-stratified serological baseline control.
PANDEMIC-to determine the impact on the population after widespread transmission and inform useful mitigation factorsDetermine cumulative incidence of infection by age(1, 28–37) reviewed in (55)Age-stratified cohort or cross-sectionalAge-stratified samples collected before emergence of novel influenza virusPrior ethics approval
Determine likelihood of further infection by ageSample size depends on estimated attack rate and precision requirementsAppropriate timing of collection at end of initial pandemic waveNational serum bank for cross-sectional studies with potential for monthly rolling sample collection throughout pandemic wave to ascertain end point accurately
Identify groups to be targeted for priority vaccination(1, 28–37, 92) reviewed in (55)Age-stratified cohort or cross-sectionalAppropriate pre-vaccination/intervention serological baseline control
Assess vaccine effectiveness and need for subsequent boosting vaccinations
Appropriate control group with same exposure to infection
Evaluate public health interventions and mitigation strategies(42, 43)
Assess decline of immunity Age-stratified longitudinal studyAccess to patientsPrior ethics approval
High patient retentionEstablished prospective representative cohort
Timely swab, sera and clinical data collection, including vaccination records and influenza-like illness reportingOutbreak response team to collect patient and contact samples and clinical data
INTERPANDEMIC-to monitor infection and vaccination throughout typical influenza seasonsAssess protection against antigenically drifted variants Age-stratified cohort or cross-sectionalAppropriate collection of samples at end of first pandemic waveNational serum bank with potential for monthly rolling sample collection
Access to emerging influenza virus drift variants
Develop novel immunological assays Age-stratified longitudinal studyTimely swab, sera and clinical data collection, including vaccination records and influenza-like illness reportingPrior ethics approval
Established prospective representative cohort
Potential for access to peripheral blood mononuclear cellsOutbreak response team to collect patient and contact samples and clinical data

Standardised methodology and data sets would greatly facilitate the ability to compare and combine serological data for each study type47 which would improve global tracking of a novel influenza virus. Identifying key elements that may be incorporated into common data collection forms, designed to accompany any blood sample intended for serological use, would enable this. Standardised reporting can be achieved by adherence to reporting guidelines of observational epidemiological studies as identified in the STROBE statement.48

Agreements to facilitate the rapid sharing of data and analyses are needed.49 Reporting of aggregated data in a standardised way will inform early decisions and facilitate the meta-analyses and substudies to further inform advisories and alerts on the development of the disease globally.50 Investigator teams should make anonymised individual-level data available freely at the time of publication, especially when important epidemiological claims are made, and, where possible, via well-managed bilateral relationships, share individual-level data with relevant health authorities as soon as those data are available. Any public health organisation in receipt of unpublished data must ensure that the interests of all stakeholders are protected. Statements from key journals that data published in surveillance bulletins and ministry health reports will not preclude later research publications, which target different audiences, would also encourage data sharing.

Coordinate and standardise the international laboratory serological response

Identification of a novel influenza virus in future outbreaks will require the rapid development of virus-specific HI and MN assays. A large quantity of the novel influenza strain isolated directly from infected individuals will need to be grown, and sera from experimental animals inoculated with the emerging virus will need to be collected for controls for assays. Optimal assay development will require panels of sera from non-exposed persons across a broad age range to determine specificity criteria and access to convalescent sera from virologically confirmed cases to define ‘true positive’ serological responses and determine sensitivity criteria.2 This may necessitate the support of clinical and epidemiological partners. It is anticipated that small scale serological testing could be performed within 6 weeks of identification of a novel influenza virus. As the severity of a novel infection remains unknown in an outbreak, virus culture and the development and expansion of early serological assays will likely include the need for BSL-3 facilities.

To expand the capacity for widespread and high-volume serological studies, in the inter-pandemic period, laboratories would need to cross-train staff in serological methods, establish quality assurance procedures and plan for surge capacity in specimen management, testing and data management. The potential for expansion of BSL-3 serological studies may be explored in laboratories currently conducting A(H5N1) serological studies. Development of a network of laboratories conducting serological studies would provide a forum for rapid distribution of methodological updates, announcements of availability of reagents and standards and discussion to achieve common seropositivity criteria. An updated Global Influenza Surveillance and Response System (GISRS) manual of influenza protocols, including serological assay protocols, is now available.51 Certain GISRS laboratories (formally GISN) with the necessary resources, especially BSL-3 facilities, should they be needed, could produce and globally distribute reagents (e.g. http://www.influenzareagentresource.org). This capacity building may require additional funding and support.

To develop data that can be combined and compared, rapid development and use of an international antibody standard and potentially common serum panels is necessary.52–54 This may be facilitated by prior commitment from (i) vaccine manufacturers to provide large volumes of sera from early clinical trials, although timeliness in vaccine development may impact this; (ii) a dedicated laboratory to produce and distribute the product and organise collaborative assignment of unitage, and (iii) global laboratories to use the standard and report normalised titres. Finally, there would be great value in the development of new high-throughput antibody-based assays to distinguish between recent infection and vaccination, and alternate specimen collection processes that overcome the limitations of venous blood collection.

Plan for outbreak studies to identify asymptomatic and symptomatic infection, enabling severity and transmissibility calculations

To calculate the strain-specific severity parameters (case or infection fatality ratio (IFR), cumulative attack rate, infection hospitalisation ratio) and transmissibility (particularly the incidence of infection for different age groups), identification of asymptomatic and symptomatic infection is needed.8 Determination of the total burden of infection in an outbreak in a structured population (such as a household or school) can provide a denominator to explain otherwise seemingly large and incompatible observed differences in severity (i.e. case fatality rate of 1:100 compared to IFR of 1:10000) and transmissibility, which greatly affect the likely later public health impact of disease. Any studies that can reliably provide early estimates of these parameters prior to large populations being infected would have great public health value.

At the time of early outbreaks, it is proposed that sample collection be enabled in multiple locations and among individuals of all age groups, providing paired sera from virologically confirmed cases for assay development and from all cases in initial small outbreak groups including contacts, to inform strain-specific parameters. The necessary sample collection may be integrated with outbreak investigation plans or routine clinical specimen collection and established epidemiological surveillance systems.

For a more structured approach, a small number of globally well-connected cities could implement prospective representative cohorts as soon as a novel strain of influenza emerges. The cohorts may include those directed to potential risk factors for severe outcomes or increased infection rates.

Early serological studies would be facilitated by their inclusion in pandemic preparedness plans. Specifically, protocols for rapid and detailed serum and data collection and processing, and ethical approvals, may be incorporated into pandemic preparedness planning, enabling a rapid response. Rapid funding strategies, such as a ‘sleeping grants’, may also be developed. Collections could be the responsibility of pre-specified healthcare professionals (outbreak response team), allowing laboratory researchers to focus on assay development. Protocols for serial sample collections from virologically confirmed individuals and collection of peripheral blood mononuclear cells may be included. As some serum samples will be collected before laboratory assays are fully developed, adequate facilities for storage and recording of samples are needed at testing laboratories or hospitals to ensure sample integrity is maintained. These proposals require advanced planning and infrastructure development that may be tested and optimised in normal influenza seasons.

Use either a cohort or a serial cross-sectional design and link serological with epidemiological and clinical data

Serological study design options are dictated by the study objectives and timing (Table 3). Serial cross-sectional studies collect samples from different individuals before and after an event, allowing for population-level analyses (e.g. cumulative incidence of infection). Anonymised discarded diagnostic or blood donations (residual sera) are often used for this, as well as sampling from individuals, although these may not be entirely representative of source populations. Cohort studies collect serial samples from the same individuals over time, enabling the analysis of changes in the immune response (e.g. generation or waning of antibody levels) following recorded events, such as infection or vaccination. Comparison of serological study designs has demonstrated little variation in the age-specific cumulative incidence of infection in the 2009 pandemic.37,55,56

Personal data and information describing potential exposure to infection with a novel strain of influenza would be of great value when collecting serological samples in defining risk factors for infection and severe outcomes. Sample date of collection, location of collection (postal code) and diagnostic test is already typically available. Personal data may encompass recent history of vaccination, socio-economic status, ethnicity, sex, residence in a group setting, date of birth, pre-disposing conditions, profession and household composition. Exposure to infection would include recent travel history, use of personal protective equipment (PPE), occupational/social contact with known-infected person(s) and antiviral drug use. For cohort studies, data collection could be specifically tailored to identify risk factors for infection or severity. The approach for data collection involving anonymised residual serum samples for cross-sectional studies may benefit from encouraging patients, clinicians and diagnostic centres to use a common data form at the time of sample donation. This approach is expensive and may only be enabled by targeting specific collection centres or constraining the requested data. A critical element would be the ability to link serum samples with these data, as well as other epidemiological and clinical data, preferably in a central database, with appropriate measures to maintain confidentiality. This would enable retrospective study whilst retaining anonymity. Unlinked anonymous (blinded) surveillance is routinely performed in HIV and vaccine preventable disease seroprevalence programmes in the UK,7,10 using a similar process.

Use national serum banks to ensure baseline serum availability and enable rolling convenience serum collections during an outbreak

The improved availability of serological samples could be addressed by annual, or biannual, collection of age-stratified, geographically representative sera, within countries. Single serum collections are currently undertaken to assess the susceptibility of a population to vaccine preventable infectious diseases11,57,58 and other infections,59,60 and where resources permit, ongoing collections are also performed.1,7,10,60–61 These current systems could be expanded to encompass more regular collections to form national serum banks, which may be used for multiple vaccine preventable diseases and other infections (e.g. HIV, dengue). Access to existing national and routine serum banks established for other purposes may also be possible with approval and support.62 Ideally, samples held in national serum banks would be complemented with vaccination history and other health information and comprise sera from children and adults, and healthy and patient donors, from a variety of sources. Crucially, the procedure for collection could be exploited during future pandemics to measure population infection at more regular intervals (monthly), ensuring key events are not missed. The collection of peripheral blood mononuclear cells may be considered to assess the complementary role of cell-mediated cross-reactive immunity; though, much larger blood volumes and immediate processing are required, which poses considerable logistic difficulties and costs.

Conduct prior research ethics review and promote public transparency on the secondary use of residual blood samples

In many countries, formal ethics review is not required when using serum samples for surveillance when investigating outbreaks and during potential public health emergencies.63,64 However, it is often difficult to distinguish when this surveillance falls into the realm of research, requiring formal ethics review. When dealing with multi-site studies, it is especially important to secure collaboration when formal ethics review is secured. Rapid response capacity would be greatly facilitated if generic protocols for investigations were developed and approved by relevant ethics review boards in advance of an outbreak. In Cambodia, for example, where serological studies are part of the national outbreak investigation plans, it is possible to seek ethical ‘pre-approval in principle’, for A(H5N1) outbreaks.65 In the UK, a pre-existing approved serosurveillance mechanism is used.1,7,10,69 Should the specifics of a particular outbreak call for changes to the sampling protocol, only the relevant changes and rationale would need to be reviewed.

Studies involving multiple institutions also benefit from streamlined ethics review processes, with centralised submission and/or review. Denmark has a system for a single ethics review of multi-site studies.66 In Australia, the National Health and Medical Research Council (NHMRC) is developing a similar system nationally where a single ethical review would be recognised by all institutions participating in a collaborative research project.67 In some countries, such as Hong Kong (China SAR), a different distinction is made and research such as seroepidemiology that cannot harm the individual is subject to a more rapid and simple review than potentially invasive studies. (Cowling B, The University of Hong Kong, Hong Kong, personal communication)

A key ethical issue concerning serological studies is whether or not consent is required for the secondary use of blood samples. For surveillance and research serological studies, use of leftover samples from blood drawn for diagnostic purposes or blood donations is common, usually with the need for individual consent or notification waived by ethics committees.1,7,64 This is generally considered ethical when it involves unlinked anonymous testing including collection of only a limited number of variables (such as age group, sex and broad locality).10,64,68,69 Whilst this approach addresses ethical and legal concerns over secondary use of samples, it restricts what can be done scientifically with the data.70 Countries with more stringent ethical restraint, especially those needing multiple local decisions, may simply not be suitable for sero-epidemiological studies in an emergency.

It has been argued that patients have a right to know that their records or specimens may be used for research64 and questionnaire-based surveys in the UK demonstrated little public knowledge of the use of residual samples,71,72 but high public support.71 Greater public transparency and discussion on the use of residual samples for research and surveillance processes may secure public confidence. Knowledge of the public health impacts of information gained from serological studies may also improve participant retention in longitudinal studies. However, individual consent-based systems pose both logistical challenges and may compromise scientific validity, depending upon response rate.7,10

It is important for researchers to maintain an ongoing relationship with their ethics committees and work with them to create solutions to address the conflicting needs for greater detail to increase the usefulness and validity of scientific evidence, and for the protection of research participants.10

Discussion and limitations

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

Serological studies complement the epidemiological and clinical studies to inform public health actions in a pandemic response. Performed early in an outbreak, they may identify both symptomatic and asymptomatic disease, providing an important denominator to calculate the severity and transmissibility of a novel virus infection. Serological studies can ascertain the population infection rates and determine the presence of pre-existing immunity generated from previous infection with influenza virus and vaccination. They can assist in identifying risk factors for infection and enable assessment of the effectiveness of vaccine and other mitigation strategies. Impressively during the 2009 pandemic and afterwards, serological studies successfully fulfilled many of these roles. We anticipate that the value of serological studies will be greatly increased by the standardisation of methods, laboratory assays, data collection, analysis and reporting. Advance planning will enable rapid and coordinated early outbreak studies that will help determine the severity of a novel influenza virus and inform subsequent action; inclusion of serological studies in national pandemic plans should be considered.

Serological studies are not without weaknesses. A minority of people did not seroconvert following virologically confirmed infection with the 2009 pandemic virus,1–3,44 antibody titres to the 2009 pandemic virus may be reduced in patients undergoing antiviral treatment44 and antibody levels may wane over time,73,74 limiting the window of detection following infection with a novel virus. Furthermore, interpretation of the results of HI and MN assays may be complicated by vaccination and ongoing circulation of identical or antigenically related strains.

Further research is needed (see Table 4). More specific and simplified assays to measure the population infection and immunity are required. Historical challenge studies suggest a correlation between higher HI titre and protection from infection,75–77 yet the contribution of other components of the immune response in mediating protection has not been assessed, nor has any age bias. Heterosubtypic antibodies may contribute to reducing influenza infection and have been shown to prevent infection in animal models.78,79 Similarly, cross-reactive T-cell immunity may also limit infection by novel influenza A strains.80 Further understanding of the contribution of the quality and quantity of the antibody and cellular response to protection from subsequent influenza infection is needed. Finally, considerations need to be given to stratified, modular study designs to allow database linkages and varying degrees of participation by different countries. To the extent possible, the creation of linkable national systems would facilitate real-time knowledge acquisition at the global level.

Table 4.   Priorities for further work
Timing for Further WorkPriorities
Immediate preparationPromote inclusion of key serological studies in principle in pandemic preparedness plans
Identify pre-existing serum banks, current collections and unlinked anonymous residual sera suitable for influenza studies
Explore the potential to obtain national ethical ‘pre-approvals in principle’ for undertaking pandemic serological studies in an emergency or outbreak
Develop national or international protocols for rapid serum sample collection, preparation and transport to laboratories in influenza outbreaks. Include the potential for dedicated outbreak response teams
Identify key elements for inclusion in data collection forms for anonymised residual sera and for samples from cohort studies
Explore the potential for clinical, serological and epidemiological data to be linked in real time
Longer term preparation and considerationUse national serum banks and unlinked anonymous residual sera and/or targeted cohorts for studies on influenza and other vaccine preventable diseases
Develop outbreak serological investigation plans (i.e. prospective cohorts) for globally well-connected cities where early transmission is likely (such as cities with major airport hubs, for example, New York, London, Hong Kong, Singapore)
Develop an international network of laboratories for conducting serological studies. Key responsibilities may include establishing commitment for production of international antibody standard(s) and control panels, and ensuring a common approach to generating comparable seroepidemiological data
Undertake relevant national seroepidemiological studies for seasonal influenza, to improve understanding of epidemiology and the impact of recent seasonal vaccination on seasonal infection and disease, and to ensure laboratory capacity for serological studies is maintained
Research gapsInvestigate potential for alternate specimen collection processes than venous blood
Develop antibody-based assays that can distinguish between recent infection and vaccination; potential for recent infection to be detected in a single acute sample
Develop less labour-intensive, but rapid, serological test methods for infection
Measure kinetics of influenza antibody decay after natural infection and vaccination in different age groups
Develop assays to measure cellular immunity and heterosubtypic antibody immunity
Explore potential to establish a correlate of protection from antibody or cellular immunity assays
Assess antigenic drift in the 2009 pandemic virus and its impact on population susceptibility

Conclusions and next steps

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

In summary, we have identified the following best practices:

  • 1
     Classify serological studies as pre-pandemic, outbreak, pandemic or inter-pandemic studies, based on time of sample collection
    2.  Standardise methodologies, prepare and agree protocols, data collection forms and reporting guidelines and make agreements for rapid data sharing
    3.  Coordinate and standardise the international laboratory serological response
    4.  Plan for early outbreak studies of novel influenza viruses to identify asymptomatic infection, enabling estimation of severity and transmissibility
    5.  Determine the best application of either cohort or serial cross-sectional designs for serological studies and link serological with epidemiological and clinical data
    6.  Use national serum banks to ensure baseline serum and rolling convenience serum collections during an outbreak
    7.  Conduct prior research ethics review and promote public transparency on the secondary use of residual blood samples

A second international meeting organised by member of the Expert Committee and supported by the European Centre for Disease Prevention and Control was planned for December 2011 in Stockholm. The goal was to initiate some of the recommendations for improving capacity for serological studies (Table 4). The potential for this guidance to encompass multiple vaccine preventable diseases and infections was also explored. However, it is important to recognise that much of our guidance for best practice requires capacity building that can only be achieved with support from public health authorities and funding bodies. To truly increase our ability to conduct serological studies will require resources as well as ongoing national and international collaboration.

Addendum

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

ICMJE criteria for authorship met: KLL developed first outline of issues, PH developed first draft of article. KLL, PH, SR, JMK, DJW, JST, AWM, KH, EM, KV, EB, MDVK and AN contributed to the writing of the article, and after critical review, all authors finalised the text of the manuscript. EB and AN drafted initial Tables 1, 3 and 4, KLL drafted initial Table 2 and Figure 1. PH chaired the Planning Committee for the International Influenza Seroprevalence Meeting held in February 2011, EB, AN, JMK, JST, EM and KH were the members of the Planning Committee and participated in regular conference calls.

Competing interests

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf (available on request from KLL) and declare that (i) SR has support from Wellcome Trust; KH has support from National Institute of Health Research (NIHR), UK; MDVK has support from the UK Medical Research Centre and the Bill and Melinda Gates Foundation, for the submitted work; (ii) KH, on behalf of HPA, was involved in projects outside the scope of this article, which were supported by funding from Novartis, Sanofi Pasteur, Baxter and CSL Limited in the previous 3 years; JMK received support for work not submitted in this manuscript from Juvaris Inc, Nobilon-Merck Sharp and Dohme, and GlaxoSmithKline in the previous 3 years; KLL, PH, SR, DJW, JST, AWM, EM, KV, EB, MDVK and AN have no relationships that might have an interest in the submitted work in the previous 3 years; (iii) KLL, PH, SR, JMK, DJW, JST, AWM, KH, EM, KV, EB, MDVK and AN their spouses, partners, or children have no financial relationships that may be relevant to the submitted work, and (iv) KLL, PH, SR, JMK, DJW, JST, AWM, KH, EM, KV, EB, MDVK and AN have no non-financial interests that may be relevant to the submitted work.

Funding

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

The International Influenza Seroprevalence Meeting held on 9–10 February, 2011 in Ottawa, Canada, was funded and hosted by the Public Health Agency of Canada. Financial support did not impact the study design, collection, analysis or interpretation of the data, writing the report, nor the decision to submit the article for publication. The findings in this manuscript are independent of funding agreements. The manuscript underwent internal clearance as is customary for a number of the agencies involved. The opinions expressed in this article are those of the members of the Expert Committee and do not necessarily reflect those of the institutions or organisations with which they are affiliated.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References

© 2012 Blackwell Publishing Ltd. The World Health Organization retains copyright and all other rights in the manuscript of this article as submitted for publication. The authors thank all the conference participants of the International Influenza Seroprevalence Meeting as well as the conference manager, Terri Champagne and the conference coordinator, Corinne Paollilo-Lessard. The authors are grateful to Professor Anne Kelso, Dr Barbara Raymond, Dr Alicia Fry and Professor Noel Gill for critical reading of previous versions of the manuscript. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health and Ageing.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Guidance for best practices
  5. Discussion and limitations
  6. Conclusions and next steps
  7. Addendum
  8. Competing interests
  9. Funding
  10. Acknowledgements
  11. References
  • 1
    Miller E, Hoschler K, Hardelid P et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:11001108.
  • 2
    Veguilla V, Hancock K, Schiffer J et al. Sensitivity and specificity of serologic assays for the detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol 2011; 49:22102215.
  • 3
    Chen MI, Barr IG, Koh GCH et al. Serological response in RT-PCR confirmed H1N1-2009 influenza A by hemagglutination inhibition and virus neutralization assays: an observational study. PLoS One 2010; 5:e12474.
  • 4
    Iwasenko JM, Cretikos M, Paterson DL et al. Enhanced diagnosis of pandemic (H1N1) 2009 influenza infection using molecular and serological testing in intensive care unit patients with suspected influenza. Clin Infect Dis 2010; 51:7072.
  • 5
    Papenburg J, Baz M, Hamelin ME et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory-confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis 2010; 51:10331041.
  • 6
    Fineberg HV, et al. WHO Report of the Review Committee on the Functioning of the International Health Regulations (2005) and on Pandemic Influenza A (H1N1) 2009. Available from apps.who.int/gb/ebwha/pdf_files/WHA64/A64_10-en.pdf (Accessed 11 April 2012).
  • 7
    Nicoll A, Gill ON, Peckham CS et al. The public health applications of unlinked anonymous seroprevalence monitoring for HIV in the United Kingdom. Int J Epidemiol 2000; 29:110.
  • 8
    Van Kerkhove MD, Asikainen T, Becker NG et al. Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLos Med 2010; 7:e1000275.
  • 9
    National Institute of Infectious Diseases T, Japan. National Serum Reference Bank, National Epidemiological Surveillance of Vaccine-Preventable Diseases. [cited]. Available from http://idsc.nih.go.jp (Accessed 12 April 2012).
  • 10
    Osborne K, Gay N, Hesketh L, Morgan-Capner P, Miller E. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol 2000; 29:362368.
  • 11
    van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 2009; 67:301308.
  • 12
    Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 20:19451952.
  • 13
    Katz JM, Hancock K, Veguilla V et al. Serum cross-reactive antibody response to a novel influenza A(H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 2009; 58:521524.
  • 14
    Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 7258:10211025.
  • 15
    Fry AM, Hancock K, Patel M et al . The first cases of 2009 pandemic influenza A (H1N1) virus infection in the United States: a serologic investigation demonstrating early transmission. Influenza Other Respi Viruses 2012; 6:e4853.
  • 16
    Jackson ML, France AM, Hancock K et al. Serologically confirmed household transmission of 2009 pandemic influenza A(H1N1) virus during the first pandemic wave — New York City, April–May 2009. Clin Infect Dis 2011; 53:455462.
  • 17
    Johnson S, Ihekweazu C, Hardelid P et al. A seroepidemiology study of novel pandemic influenza (H1N1) 2009 during an outbreak in a boarding school. Emerg Infect Dis 2011; 17:16701677.
  • 18
    Fraser C, Donnelly CA, Cauchemez S et al. Pandemic potential of a strain of influenza A(H1N1): early findings. Science 2009; 324:15571561.
  • 19
    Lessler J, Reich NG, Cummings DAT, NYC Department of Health and Mental Hygiene Swine Influenza Investigation Team. Outbreak of 2009 pandemic influenza A(H1N1) at a New York City school. N Engl J Med 2009; 361:26282836.
  • 20
    McBryde ES, Bergeri I, van Gemert C et al. Early transmission characteristics of influenza A(H1N1)v in Australia: Victorian state, 16 May-3 June 2009. Eurosurveillance 2009; 14:19363.
  • 21
    Smith A, Coles S, Johnson S, Saldana L, Ihekweazu C, O’Moore É. An outbreak of influenza A(H1N1)V in a boarding school in south east England, May-June 2009. Eurosurveillance 2009; 14:pii=19263.
  • 22
    Maines TR, Jayaraman A, Belser JA et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009; 325:484487.
  • 23
    Munster VJ, de Wit E, van den Brand JM et al. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325:481483.
  • 24
    ANZIC II. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:19251934.
  • 25
    Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374:451458.
  • 26
    Nguyen-Van-Tam JS, Openshaw PJ, Hashim A et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010; 65:645651.
  • 27
    Van Kerkhove MD, Vandemaele K, Shinde V et al. on behalf of the WHO Working Group on Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 Influenza A (H1N1) infection: a global pooled analysis. PLos Med 2011; 8:e1001053.
  • 28
    Bandaranayake D, Huang QS, Bissielo A et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS One 2010; 5:e13211.
  • 29
    Chen MIC, Lee VJM, Lim WY et al. 2009 Influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 2010; 303:13831391.
  • 30
    Dowse GK, Smith DW, Kelly H et al. Incidence of pandemic (H1N1) 2009 influenza infection in children and pregnant women during the 2009 influenza season in Western Australia — a seroprevalence study. Med J Aust 2011; 194:6872.
  • 31
    Gilbert GL, Cretikos MA, Hueston L, Doukas G, O’Toole B, Dwyer DE. Influenza A(H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 Southern Hemisphere winter. PLoS One 2010; 5:e12562.
  • 32
    McVernon J, Laurie KL, Nolan T et al. Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October–December 2009. Eurosurveillance 2010; 15:19678.
  • 33
    Tandale BV, Pawar SD, Gurav YK et al. Seroepidemiology of pandemic influenza A(H1N1) 2009 virus infections in Pune, India. BMC Infect Dis 2010; 10:255.
  • 34
    Waalen K, Kilander A, Dudman SG, Krogh GH, Aune T, Hungnes O. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009. Eurosurveillance 2010; 15:19633.
  • 35
    Wu JT, Ma ESK, Lee CK et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 2010; 51:11841191.
  • 36
    Xu C, Bai T, Iuliano AD et al. The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS One 2011; 6:e17919.
  • 37
    Riley S, Kwok KO, Wu KM et al. Epidemiological characteristics of 2009 pandemic influenza based on paired sera from a prospective community cohort. PLos Med 2011; 8:e1000442.
  • 38
    Jaeger J, Patel M, Dharan N et al. Transmission of 2009 pandemic influenza A(H1N1) virus among healthcare personnel-Southern California, 2009. Infect Control Hosp Epidemiol 2011; 32:11491157.
  • 39
    Chen MI, Lee VJ, Barr I et al. Risk factors for pandemic (H1N1) 2009 virus seroconversion among hospital staff, Singapore. Emerg Infect Dis 2010; 16:15541561.
  • 40
    Trauer JM, Laurie K, McDonnell J, Kelso A, Markey PG. Differential impact of pandemic (H1N1) 2009 on remote and Indigenous groups in the Northern Territory, Australia. Emerg Infect Dis 2011; 17:16151623.
  • 41
    Mahmud SM, Becker M, Keynan Y et al. Estimated cumulative incidence of pandemic (H1N1) influenza among pregnant women during the first wave of the 2009 pandemic. Can Med Assoc J 2010; 182:15221524.
  • 42
    Lee VJ, Yap J, Cook AR et al. Effectiveness of public health measures in mitigating pandemic influenza spread: a prospective sero-epidemiological cohort study. J Infect Dis 2010; 202:13191326.
  • 43
    Lee VJ, Yap J, Tay JK et al. Seroconversion and asymptomatic infections during oseltamivir prophylaxis against influenza A H1N1 2009. BMC Infect Dis 2010; 10:164.
  • 44
    Cowling BJ, Chan KH, Fang VJ et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010; 362:21752184.
  • 45
    Aho M, Lyytikainen O, Nyholm JE et al. Outbreak of 2009 pandemic influenza A(H1N1) in a Finnish garrison – a serological survey. Eurosurveillance 2011; 15:19709.
  • 46
    Wood J, Heath A. Report of a WHO Collaborative Study to Assess the Suitability of a Candidate International Standard for Antibody to Pandemic H1N1 Influenza Virus. WHO Press, World Health Organization, 2010. Contract No.: Document Number|WHO/BS/10.2137.
  • 47
    WHO. Seroepidemiologic studies for the 2009 influenza A H1N1 pandemic. Wkly Epidemiol Rec 2010; 85:229236.
  • 48
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLos Med 2007; 4:e296.
  • 49
    European Union Council. Decision No 2119/98/EC. L 268 ed; 1998. p. P. 0001-7. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998D2119:EN:HTML (Accessed 12 April 2012).
  • 50
    Witt CJ, Richards AL, Masuoka PM et al. The AFHSC-Division of GEIS Operations Predictive Surveillance Program: a multidisciplinary approach for the early detection and response to disease outbreaks. BMC Public Health 2011; 11(Suppl 2):S10.
  • 51
    World Health Organization GISN. Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. 2011. [updated 2011; cited]; Available from http://www.who.int/influenza/resources/documents/manual_diagnosis_surveillance_influenza/en/ (Accessed 12 April 2012).
  • 52
    Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007; 25:40564063.
  • 53
    Stephenson I, Heath A, Major D et al. Reproducibility of serologic assays for influenza virus A(H5N1). Emerg Infect Dis 2009; 15:12501259.
  • 54
    Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167174.
  • 55
    Kelly H, Peck HA, Laurie KL, Wu P, Nishiura H, Cowling BJ. The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS One 2011; 6:e21828.
  • 56
    Broberg E, Nicoll A, Amato-Gauci A. Seroprevalence to influenza A(H1N1) 2009 virus – where are we? Clin Vaccine Immunol 2011; 18:120512.
  • 57
    Andrews N, Tischer A, Sledler A et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ 2008; 86:197204.
  • 58
    Cagney M, MacIntyre CR, McIntyre P, Puech M, Giammanco A. The seroepidemiology of pertussis in Australia during an epidemic period. Epidemiol Infect 2006; 134:12081216.
  • 59
    Chandy S, Yoshimatsu K, Ulrich RG et al. Seroepidemiological study on hantavirus infections in India. Trans R Soc Trop Med Hyg 2008; 102:7074.
  • 60
    Forshey BM, Guevara C, Laguna-Torres VA et al. Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007. PLoS Negl Trop Dis 2010; 10:e787.
  • 61
    Hardelid P, Andrews NJ, Hoschler K et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 2010; 14:115192.
  • 62
    CDC. National Health and Nutrition Examination Survey, Serum Samples III. [cited]; Available from http://www.cdc.gov/nchs/nhanes/genetics/stored_specimens.htm (Accessed 12 April 2012).
  • 63
    NHS. Facilitating and Promoting Ethical Research. 2011. [updated 2011; cited]; Available from http://www.nres.nhs.uk/applications/is-your-project-research/ (Accessed 12 April 2012).
  • 64
    WHO-CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects. 2002. [updated 2002; cited]; Available from http://www.fhi.org/training/fr/retc/pdf_files/cioms.pdf (Accessed April 12 2012).
  • 65
    Vong S, Ly S, Van Kerkhove M et al. Risks for H5N1 infections from Poultry to Humans in Cambodia, 2006. J Infect Dis 2009; 199:19.
  • 66
    Holm S. The Danish Research Ethics Committee System, Overview and Critical Assessment (Research Involving Human Participants V2). [cited 2011 July 8]; Available from http://www.onlineethics.org/cms/8082.aspx (Accessed 12 April 2012).
  • 67
    NHMRC. Harmonisation of Multi-Centre Ethical Review (HoMER). [cited]; Available from http://www.nhmrc.gov.au/health_ethics/homer/index.htm (Accessed 12 April 2012).
  • 68
    Heptonstall J, Gill ON. The legal and ethical basis for unlinked anonymous HIV Testing. CDR Weekly 1989; 89:36. Available from http://www.hpa.org.uk/cdr/archives/HIV-AIDS_1983-1990/1989/1989_wk48_pgs3-6.pdf (Accessed 12 April 2012).
  • 69
    Hepple B, Smith P, Brownsword R et al. Public Health: Ethical Issues. London: Nuffield Council on Bioethics, 2007. Available at http://www.scribd.com/doc/1110307. (Accessed 12 April 2012).
  • 70
    Gill ON, Adler MW, Day NE. Monitoring the prevalence of HIV. Br Med J 1989; 299:12951298.
  • 71
    Datta J, Kessel A, Wellings K et al. The views of genitourinary medicine (GUM) clinic users on unlinked anonymous testing for HIV: evidence from a pilot study of clinics in two English cities. J Med Ethics 2011; 37:668672.
  • 72
    Kessel A, Watts C, Weiss HA. Bad blood? Survey of public’s views on unlinked anonymous testing of blood for HIV and other diseases. Br Med J 2000; 320:e1.
  • 73
    Ochiai H, Shibata M, Kamimura K, Niwayama S. Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity and persistence of antibodies following two doses of vaccines. Microbiol Immunol 1986; 30:11411149.
  • 74
    Song JY, Cheong HJ, Hwang IS et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28:39293935.
  • 75
    Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767777.
  • 76
    Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:6975.
  • 77
    Fox JP, Cooney MK, Hall CE, Foy HM. Influenzavirus infections in Seattle families, 1975–1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 1982; 116:228242.
  • 78
    Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope: implications for universal prevention and therapy. Science 2009; 324:246251.
  • 79
    Sui J, Hwang W, Perez S et al. Structural and functional bases from broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265273.
  • 80
    Greenbaum JA, Kotturi MF, Kim Y et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:2036520370.
  • 81
    Nicoll A, Ammon A, Amato Gauci A et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health 2010; 124:1423.
  • 82
    Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expt Rev Anti Infect Ther 2011; 9:669683.
  • 83
    Zambon M. Laboratory diagnosis of influenza; in Nicholson KG, Webster RG, Hay AJ (eds): Textbook of Influenza. Oxford: Blackwell Science, 1998; pp. 291313.
  • 84
    Chang SC, Chang CM, Huang YC, Chiu CH, Shih SR, Lin TY. Preexisitng antibodies against pandemic 2009 influenza A(H1N1) virus in Taiwan. Clin Infect Dis 2010; 51:14651467.
  • 85
    Chen H, Wang Y, Liu W, Zhang J, Dong B, Fan X. Serological survey of pandemic (H1N1) 2009 virus, Guanxi Province, China. Emerg Infect Dis 2009; 15:18491850.
  • 86
    Tang JW, Tambyah PA, Wilder-Sminth A, Puong K-Y, Shaw R, Barr IG. Cross-reactive antibodies to influenza (H1N1) 2009 virus, Singapore. Emerg Infect Dis 2010; 16:874876.
  • 87
    Ikonen N, Strengell M, Kinnunen L et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Eurosurveillance 2010; 15:19478.
  • 88
    Rizzo C, Rota MC, Bella A et al. Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period. Vaccine 2010; 28:35583562.
  • 89
    Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 25:24142423.
  • 90
    Jiang T, Li X, Liu W et al. Serum antibody response to the novel influenza A(H1N1) virus in the elderly. Clin Infect Dis 2010; 50:285286.
  • 91
    Chi CY, Liu CC, Lin CC et al. Preexisiting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 2010; 17:19581962.
  • 92
    Chan YJ, Lee CL, Hwang SJ et al. Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. J Chin Med Assoc 2010; 73:6266.